financetom
Business
financetom
/
Business
/
ChargePoint Reports Better-Than-Expected Q1 Results: The Details
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ChargePoint Reports Better-Than-Expected Q1 Results: The Details
Jun 5, 2024 1:52 PM

ChargePoint Holdings, Inc. ( CHPT ) reported its first-quarter financial results after the bell Wednesday. Here's a look at the key figures from the report.

The Details:

ChargePoint ( CHPT ) reported quarterly losses of 17 cents per share which beat the analyst consensus estimate of losses of 18 cents by 5.56%.

The company reported quarterly sales of $107 million which beat the analyst consensus estimate of $105.791 million by 1.14% and represents a 17.71% decrease from the same period last year.

Networked charging systems revenue for the first quarter was $65.4 million, down 34% from $98.3 million in the prior year’s same quarter. Subscription revenue was $33.4 million, up 27% from $26.4 million in the prior year’s same quarter.

“ChargePoint delivered as anticipated in the first quarter. We achieved revenue above the midpoint of our guidance range, sequential gross margin improvements, meaningful reduction in operating expenses, and an improvement in non-GAAP adjusted EBITDA loss,” said Rick Wilmer, CEO of ChargePoint ( CHPT ).

“We remain focused on operational excellence, which will enable us to continue to deliver great driver experiences and be the platform of choice for everyone who wants to offer EV charging.”

Outlook: 

ChargePoint ( CHPT ) sees second-quarter revenue in a range of $108 million and $118 million, versus the $121.35 million consensus estimate. The company reaffirmed its goal to achieve positive non-GAAP Adjusted EBITDA for the fourth quarter of fiscal year 2025 ending January 31, 2025.

Related News: What’s Going On With Novavax Stock?

CHPT Price Action: According to Benzinga Pro, ChargePoint ( CHPT ) shares are up 0.58% after-hours at $1.73 at the time of publication Wednesday.

Image: Gerd Altmann from Pixabay

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China anti-monopoly regulator launches probe into Google
China anti-monopoly regulator launches probe into Google
Feb 3, 2025
BEIJING (Reuters) - China's anti-monopoly regulator said on Tuesday it had launched an investigation into Alphabet's Google, minutes after an additional 10% tariff on Chinese goods imposed by U.S. President Donald Trump came into effect. The investigation by China's State Administration of Market Regulation was announced as Beijing also slapped tariffs on some U.S. products such as coal and oil...
UBS quarterly profit smashes expectations, $3 billion buyback unveiled
UBS quarterly profit smashes expectations, $3 billion buyback unveiled
Feb 3, 2025
ZURICH (Reuters) - UBS Group, Switzerland's largest bank, on Tuesday posted net income of $770 million for the fourth quarter of 2024, trouncing forecasts. The net profit attributable to shareholders compared with an average estimate of $483 million in a company-provided poll of analysts. The lender also announced a share buyback program of up to $3 billion for this year,...
US dollar ratchets higher as China tariffs kick in; Aussie slides with yuan
US dollar ratchets higher as China tariffs kick in; Aussie slides with yuan
Feb 3, 2025
TOKYO (Reuters) -The dollar strengthened broadly on Tuesday after U.S. tariffs on Chinese goods came into effect, triggering swift retaliation from Beijing and prompting a selloff in the Chinese yuan and the Australian dollar. The Canadian dollar and Mexican peso also weakened despite earlier winning a reprieve on their own U.S. tariffs. The euro declined, with the European Union also...
FOCUS-Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
FOCUS-Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Feb 3, 2025
* Novo Nordisk losing ground to Eli Lilly ( LLY ) in obesity drug race * CagriSema trial data wiped $125 billion off Novo shares * Investors frustrated at silence from company after data release * Novo may disclose more info from trial at Q4 results on Feb. 5 * CagriSema trial participants say drug effective, side-effects difficult By Maggie...
Copyright 2023-2025 - www.financetom.com All Rights Reserved